HR-9759-119
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Judiciary, Oversight and Government Reform, Education and Workforce, and Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsored by Chris Pappas (D-NH)
What it does
The Turn the Tide Act would appropriate and authorize roughly $20+ billion over four to five fiscal years (2027–2031) across dozens of existing federal programs targeting opioid and substance use disorders. It would eliminate prior authorization requirements for medication-assisted treatment under Medicaid, require private insurance and Medicare Part D to cover at least one opioid overdose reversal agent (such as naloxone) with no cost-sharing, raise Medicaid reimbursement rates for behavioral and mental health providers to Medicare parity levels, and fund a demonstration project testing recovery housing under Medicaid. It would also expand state opioid response grants, drug court programs, first responder training, recovery housing, and workforce loan repayment programs, with priority weighting toward states with the highest overdose death rates.
Who benefits
People with opioid use disorder or other substance use disorders, particularly Medicaid enrollees who would face fewer insurance barriers to medication-assisted treatment. Unhoused individuals with opioid use disorder who may gain access to recovery housing. Pregnant and postpartum women in residential treatment programs. Children affected by trauma related to household substance use. First responders trained in overdose response. Behavioral health clinicians and clinical social workers who would receive higher Medicaid reimbursement rates. Substance use disorder treatment workforce members eligible for expanded loan repayment. Community recovery coalitions receiving Drug-Free Communities grants. States with high overdose mortality rates, which would receive priority funding. Indian Tribes and Tribal organizations, which receive a dedicated $50 million set-aside annually. Rural and economically disadvantaged communities served by targeted grant programs. Insurers and pharmacy benefit managers who gain regulatory clarity on coverage mandates.
Who is hurt
Private health insurers and employer-sponsored health plans that would be required to cover overdose reversal agents with no cost-sharing, potentially shifting those costs to premiums paid by all enrollees. States that currently pay Medicaid providers below Medicare rates would face administrative and fiscal transition costs, even with a temporary 100% federal match for the rate increase. States with lower overdose mortality rates would receive proportionally less funding under the priority-weighted formulas. Competing federal health priorities may face reduced attention or future appropriations pressure given the scale of mandatory spending. Taxpayers broadly, as the bill appropriates funds "out of any monies in the Treasury not otherwise appropriated," adding to federal expenditures without offsetting revenue measures. Drug court and law enforcement programs in lower-need states may receive less competitive grant funding under the new priority criteria.
Supporters argue
Supporters argue that the opioid crisis has killed more than 500,000 Americans since 1999, with over 80,000 overdose deaths recorded in 2023 alone, and that the existing patchwork of underfunded programs has failed to meet the scale of the epidemic. They contend that eliminating prior authorization barriers for medication-assisted treatment directly addresses a documented bottleneck — studies show prior authorization delays reduce treatment initiation and increase relapse rates — and that requiring zero-cost-sharing for naloxone could prevent thousands of deaths annually given that the drug is safe, inexpensive, and highly effective when administered promptly. They further argue that raising Medicaid reimbursement rates to Medicare parity is necessary to expand the behavioral health workforce, as low rates have driven providers out of Medicaid networks and left patients without accessible care.
Opponents argue
Opponents argue that the bill appropriates tens of billions of dollars in mandatory spending without offsets, adding substantially to the federal deficit at a time of fiscal strain, and that the "out of any monies in the Treasury not otherwise appropriated" mechanism bypasses the normal annual appropriations process, reducing congressional oversight and accountability. They contend that mandating zero cost-sharing for overdose reversal agents across all private plans and Medicare Part D shifts costs to all premium-payers regardless of their risk profile, and that the Medicaid provider rate mandate — even with a temporary 100% federal match — creates a structural spending increase that states will be expected to sustain after the match expires in 2030. They further argue that the bill's broad grant flexibility and multi-agency scope may dilute effectiveness, as prior large-scale substance use funding packages have shown mixed results in reducing overall overdose mortality.
Constitutional context
Congress is acting under the Taxing and Spending Clause (Art. I, §8, cl. 1) and the Commerce Clause (Art. I, §8, cl. 3) to fund grants, regulate insurance markets, and set Medicaid payment conditions. The Medicaid provider rate mandates and prior authorization prohibitions are conditions on federal Medicaid funding; under NFIB v. Sebelius (2012), such conditions must not be so coercive as to leave states no genuine choice, though the bill's 100% federal match for incremental costs and its temporary scope reduce the coercion risk. Post-Loper Bright (2024), agency regulations implementing the bill's broad delegations — such as the Secretary's authority to define "utilization control policies" — would face independent judicial scrutiny rather than deferential review.
Checks and balances
Congress gains significant spending authority through mandatory appropriations bypassing the annual appropriations process; HHS, ONDCP, and DOJ implement the programs; states retain some discretion in grant use but face new Medicaid payment mandates; courts retain authority to review agency rules implementing broad delegations under the post-Loper Bright independent judgment standard.
Historical precedent
The SUPPORT for Patients and Communities Act of 2018 (Public Law 115-271), which this bill directly reauthorizes and expands, was the largest federal legislative response to the opioid crisis to date and established most of the program structures this bill would refund and modify.